U.S. Court of Appeals Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit
In the inter partes review (IPR) proceedings initiated by
If the patent is ultimately upheld through all remaining challenges, Alimta would maintain U.S. exclusivity until
"We are pleased with today's ruling by the Appeals Court finding the claims of the Alimta vitamin regimen patent are valid," said
"Lilly's extensive research to discover the Alimta vitamin regimen patent deserves intellectual property protection, which has been confirmed in every validity challenge in the U.S. to date," Harrington said. "We depend on strong and effective intellectual property protection to help support the development of the next generation of innovative medicines."
On
In a separate decision on
These rulings mean
In
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels. C-LLY
This release contains forward-looking statements regarding the U.S. Alimta patent litigation. These statements are based on management's current expectations but actual results may differ materially. There can be no assurance that the company will prevail in any litigation or appeal. Also, the company cannot predict whether generic pemetrexed will be marketed in the U.S. prior to the expiration of the vitamin regimen patent. Other risk factors that may affect the company's results can be found in the company's latest Forms 10-K and 10-Q filed with the
________________________________
Alimta® (pemetrexed for injection, Lilly)
Refer to: |
Scott MacGregor; jsmacgregor@lilly.com; +1 317-440-4699 (Media) |
Kevin Hern; hern_kevin_r@lilly.com; +1 317-277-1838 (Investors) |
View original content to download multimedia:http://www.prnewswire.com/news-releases/us-court-of-appeals-rules-in-favor-of-lilly-in-alimta-vitamin-regimen-patent-lawsuit-300839069.html
SOURCE